- For patients with second-line (2L) metastatic pancreatic cancer, today’s FDA approval of a new tre

- For patients with second-line (2L) metastatic pancreatic cancer, today's FDA approval of a new tre

Wall Street analysts change outlook on top names. Check analyst ratings page for all changes. See wh

Wall Street analysts made some dramatic moves on Thursday, slashing price targets by double digits o

HC Wainwright & Co. analyst Andres Y. Maldonado initiates coverage on Immuneering (NASDAQ:IMR

Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.27) per share which met the analyst conse

- 17.3 month median overall survival in 55 first-line pancreatic cancer patients treated with atebim

Immuneering Corporation targets first-line pancreatic cancer with atebimetinib, showing promising Ph

- Atebimetinib showed broad antitumor activity across KRAS-, NRAS-, and BRAF-mutant models, includin

- Atebimetinib showed broad antitumor activity across KRAS-, NRAS-, and BRAF-mutant models, includin

Needham analyst Ami Fadia maintains Immuneering (NASDAQ:IMRX) with a Buy and raises the price tar

NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage cli

Immuneering (IMRX) might move higher on growing optimism about its earnings prospects, which is refl

Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping can

- Former CFO of Terns Pharmaceuticals to join Immuneering - - Seasoned public company CFO strengthen

Immuneering stock rises after dosing the first patient in a pivotal phase III study of atebimetinib

Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping can

Global pivotal Phase 3 trial will evaluate efficacy and safety of atebimetinib + modified gemcitabin

Immuneering Corporation (IMRX) Discusses Positive Atebimetinib ASCO Data Update in First-Line Pancre

- 17.3 months median overall survival in 55 first-line pancreatic cancer patients; vs. 8.5 months fo

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with A

US stocks rose, Dow gained over 400 points. S&P 500 and NASDAQ also up. Health care shares jumpe

Zoom Communications Inc shares rise after strong financial results and increased buyback authorizat

Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping can

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer P

Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.21) per share which beat the analyst cons

- New survival data from Phase 2a clinical trial evaluating atebimetinibmGnP in first-line metastati

Immuneering Corporation (IMRX) presents promising early data in frontline metastatic pancreatic canc

- New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic canc

- New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic canc

Analysis of circulating tumor DNA from atebimetinib-treated patients shows acquired MAPK pathway alt

Immuneering (NASDAQ: IMRX) CEO Benjamin J. Zeskind told investors at a Needham conference session th

Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping can

Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.18) per share which beat the analyst cons

Benzinga examined the prospects for many investors' favorite stocks over the last week — here&#3

Immuneering shares traded lower after new pancreatic cancer trial data showed improved survival, man

(Editor’s note: The future prices of benchmark tracking ETFs and the headline were updated in the st

Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping can

Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping ca